BioNTech SE(BNTX) - 2024 Q1 - Quarterly Report

GlaxoSmithKline Proceedings Overview Cash Flow Net cash used in operating activities for the three months ended March 31, 2024, was €317.3 million, comprising a loss before tax of €331.8 million, negative non-cash adjustments of €151.7 million, and a net positive change in assets and liabilities of €222.5 million. Non-cash items primarily included finance income as well as depreciation of property, plant and equipment and other intangible assets without cash-effect. The net positive change in assets and lia ...